BENGALURU] European shares ended slightly higher on Tuesday (Apr 22) on the back of rising financials and post-earnings gains ...

The health-care industry group of the S&P 500 has fought back to near the flat line for the year to date. Orchestra BioMed Holdings shares initially surged after the maker of medical devices said a ...

The Danish pharma giant's shares fell by up to 9% after Eli Lilly announced that its experimental daily pill may work just as ...

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Novo Nordisk, maker of Ozempic, applied for FDA approval for a weight loss pill, less than a week after rival Eli Lilly's clinical trial success.

Detailed price information for Eli Lilly and Company (LLY-N) from The Globe and Mail including charting and trades.

Many compounding pharmacies are no longer allowed to make cheaper versions of semaglutide and other GLP-1 drugs. A doctor ...

During oral arguments, the defendants contended that the plaintiffs could not support their allegations that Novo Nordisk and ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

The stock fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant ...